Christopher McGuigan
About
In The Last Decade
Christopher McGuigan
243 papers receiving 5.9k citations
Peers
Comparison fields: 5 of 116
- Infectious Diseases 3.0k
- Molecular Biology 2.7k
- Organic Chemistry 1.9k
- Epidemiology 1.9k
- Virology 1.0k
Countries citing papers authored by Christopher McGuigan
This map shows the geographic impact of Christopher McGuigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher McGuigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher McGuigan more than expected).
Fields of papers citing papers by Christopher McGuigan
This network shows the impact of papers produced by Christopher McGuigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher McGuigan. The network helps show where Christopher McGuigan may publish in the future.
Co-authorship network of co-authors of Christopher McGuigan
This figure shows the co-authorship network connecting the top 25 collaborators of Christopher McGuigan. A scholar is included among the top collaborators of Christopher McGuigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher McGuigan. Christopher McGuigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 12 | |
| 5 | NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival | 2 |
| 6 | 7 | |
| 7 | 62 | |
| 8 | Pre-clinical development of the BCNAs: The most potent anti-VZV agents reported to date | 1 |
| 9 | SAR of alkyloxyphenyl furano pyrimidines: Potent and selective anti-VZV agents | 2 |
| 10 | Synthesis and biological evaluation of N- and O-alkylated bicyclic furanopyrimidines as non-nucleosidic inhibitors of human cytomegalovirus | 1 |
| 11 | Synthesis and biological evaluation of bicyclic furano pyrimidine nucleosides as inhibitors of human cytomegalovirus | 2 |
| 12 | New bicyclic nucleoside analogues (BCNAs) show selective and specific activity against human cytomegalovirus (HCMV) | 1 |
| 13 | Discovery of a new family of bicyclic dideoxy nucleosides which inhibit HCMV by a non-nucleoside mechanism | 1 |
| 14 | Anti-varicella-zoster virus bicyclic nucleosides: Synthesis and in vitro evaluation of 2 ',3 '-dideoxy nucleoside derivatives | 1 |
| 15 | Susceptibilities of several drug-resistant varicella-zoster virus (VZV) strains to bicyclic pyrimidine nucleoside analogues (BCNAs) | 3 |
| 16 | 46 | |
| 17 | 7 | |
| 18 | 21 | |
| 19 | 17 | |
| 20 | 53 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.